Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Automotive-focused visual technology startup Spyne has raised $16 million in a Series A funding round led by Vertex Ventures ... reality (AR)/virtual reality (VR) solutions, Varnwal added.

Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...

Vertex reports Q4 earnings Monday, with Wall Street expecting $4.03 EPS and $2.78 billion revenue. Strong technicals support VRTX stock, but selling pressure and pipeline execution remain key ...

Feb 10 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and ...